Arrowhead Pharmaceuticals's three largest insider shareholders as of July 24, 2026 are Christopher Richard Anzalone (Chief Executive Officer, 3.79Mn shares), Patrick O'Brien (Coo, 547.41K shares), Kenneth Allen Myszkowski (Chief Financial Officer, 455.43K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Christopher Richard Anzalone | Chief Executive Officer | 3,792,739 | 0 | 05 Jan, 2026 |
| Kenneth Allen Myszkowski | Chief Financial Officer | 455,433 | 0 | 07 Jan, 2025 |
| Mauro Ferrari | - | 69,053 | 0 | 30 Dec, 2025 |
| William D. Waddill | - | 56,563 | 0 | 23 Dec, 2025 |
| Patrick O'Brien | Coo | 547,408 | 0 | 08 Jan, 2026 |
| Victoria Vakiener | - | 35,723 | 0 | 23 Dec, 2025 |
| James C Hamilton | Chief Medical Officer | 226,958 | 0 | 24 Apr, 2026 |
| Tracie Oliver | Chief Commercial Officer | 127,107 | 0 | 03 Jul, 2024 |
| Daniel Joseph Apel | Chief Financial Officer | 162,905 | 0 | 24 Apr, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 22 Apr, 2026 | Daniel Joseph Apel | Common Stock | D | 3,208 | $70.11 | 172,792 | D | S |
| 23 Apr, 2026 | James C Hamilton | Common Stock | D | 10,000 | $75.00 | 226,958 | D | S |
| 22 Apr, 2026 | Daniel Joseph Apel | Common Stock | D | 1,157 | $70.45 | 171,635 | D | S |
| 22 Apr, 2026 | Daniel Joseph Apel | Common Stock | D | 8,730 | $71.92 | 162,905 | D | S |
| 06 Jan, 2026 | Patrick O'Brien | Common Stock | D | 540 | $0.00 | 474,368 | D | G |
| 06 Jan, 2026 | Patrick O'Brien | Common Stock | D | 540 | $0.00 | 474,368 | D | G |
| 06 Jan, 2026 | Patrick O'Brien | Common Stock | D | 540 | $0.00 | 474,368 | D | G |
| 06 Jan, 2026 | Patrick O'Brien | Common Stock | D | 540 | $0.00 | 474,368 | D | G |
| 06 Jan, 2026 | Patrick O'Brien | Common Stock | D | 540 | $0.00 | 473,828 | D | G |
| 06 Jan, 2026 | Patrick O'Brien | Common Stock | D | 540 | $0.00 | 473,828 | D | G |
| 06 Jan, 2026 | Patrick O'Brien | Common Stock | D | 540 | $0.00 | 473,828 | D | G |
| 06 Jan, 2026 | Patrick O'Brien | Common Stock | D | 540 | $0.00 | 473,828 | D | G |
| 06 Jan, 2026 | Patrick O'Brien | Common Stock | D | 540 | $0.00 | 473,288 | D | G |
| 06 Jan, 2026 | Patrick O'Brien | Common Stock | D | 540 | $0.00 | 473,288 | D | G |
| 06 Jan, 2026 | Patrick O'Brien | Common Stock | D | 540 | $0.00 | 473,288 | D | G |
| 06 Jan, 2026 | Patrick O'Brien | Common Stock | D | 540 | $0.00 | 473,288 | D | G |
| 06 Jan, 2026 | Patrick O'Brien | Common Stock | D | 440 | $0.00 | 472,848 | D | G |
| 06 Jan, 2026 | Patrick O'Brien | Common Stock | D | 440 | $0.00 | 472,848 | D | G |
| 06 Jan, 2026 | Patrick O'Brien | Common Stock | D | 440 | $0.00 | 472,848 | D | G |
| 06 Jan, 2026 | Patrick O'Brien | Common Stock | D | 440 | $0.00 | 472,848 | D | G |